With plans in place to expand clofarabine's label from pediatric acute lymphoblastic leukemia (ALL) to adult acute myeloid leukemia (AML), Genzyme Corp. moved to acquire partner Bioenvision Inc. in an all-cash deal worth approximately $345 million. (BioWorld Today)

With plans in place to expand clofarabine's label from pediatric acute lymphoblastic leukemia (ALL) to adult acute myeloid leukemia (AML), Genzyme Corp. moved to acquire partner Bioenvision Inc. in an all-cash deal worth approximately $345 million. (BioWorld Today)